Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

E1s and E2s first work generically across the cell to activate and prepare ubiquitin for attachment. E3 ligases then ensure that the tag is added to the right protein; as such, hundreds of specific ...

Empa researchers have developed a new 3D tissue analysis for thyroid tumors. This special X-ray technique uses artificial ...

Imaging technology developed and refined at the University of Waterloo promises better detection and treatment of breast cancer by more accurately pinpointing cancerous tissue.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it has garnered the "Cancer Immunology Solution of the Year" award in the fourth annual ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Photoimmunotherapy with the M@P nanoplatform offers a novel approach, triggering cancer cell death and boosting immune ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice.